Loading…

Potentiation and tolerance of toll-like receptor priming in human endothelial cells

Repeated challenge of lipopolysaccharide (LPS) alters the response to subsequent LPS exposures via modulation of toll-like receptor 4 (TLR4). Whether activation of other TLRs can modulate TLR4 responses, and vice versa, remains unclear. Specifically with regards to endothelial cells, a key component...

Full description

Saved in:
Bibliographic Details
Published in:Translational research : the journal of laboratory and clinical medicine 2017-02, Vol.180, p.53-67.e4
Main Authors: Koch, Stephen R, Lamb, Fred S, Hellman, Judith, Sherwood, Edward R, Stark, Ryan J
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c580t-d589d27a62ed1cdc2056fad190d79d33c97758e1dc10f6774a273b4f867374f03
cites cdi_FETCH-LOGICAL-c580t-d589d27a62ed1cdc2056fad190d79d33c97758e1dc10f6774a273b4f867374f03
container_end_page 67.e4
container_issue
container_start_page 53
container_title Translational research : the journal of laboratory and clinical medicine
container_volume 180
creator Koch, Stephen R
Lamb, Fred S
Hellman, Judith
Sherwood, Edward R
Stark, Ryan J
description Repeated challenge of lipopolysaccharide (LPS) alters the response to subsequent LPS exposures via modulation of toll-like receptor 4 (TLR4). Whether activation of other TLRs can modulate TLR4 responses, and vice versa, remains unclear. Specifically with regards to endothelial cells, a key component of innate immunity, the impact of TLR cross-modulation is unknown. We postulated that TLR2 priming (via Pam3Csk4) would inhibit TLR4-mediated responses while TLR3 priming (via Poly I:C) would enhance subsequent TLR4-inflammatory signaling. We studied human umbilical vein endothelial cells (HUVECs) and neonatal human dermal microvascular endothelial cells (HMVECs). Cells were primed with a combination of Poly I:C (10 μg/ml), Pam3Csk4 (10 μg/ml), or LPS (100 ng/ml), then washed and allowed to rest. They were then rechallenged with either Poly I:C, Pam3Csk4 or LPS. Endothelial cells showed significant tolerance to repeated LPS challenge. Priming with Pam3Csk4 also reduced the response to secondary LPS challenge in both cell types, despite a reduced proinflammatory response to Pam3Csk4 in HMVECs compared to HUVECs. Poly I:C priming enhanced inflammatory and interferon producing signals upon Poly I:C or LPS rechallenge, respectively. Poly I:C priming induced interferon regulatory factor 7, leading to enhancement of interferon production. Finally, both Poly I:C and LPS priming induced significant changes in receptor-interacting serine/threonine-protein kinase 1 activity. Pharmacological inhibition of receptor-interacting serine/threonine-protein kinase 1 or interferon regulatory factor 7 reduced the potentiated phenotype of TLR3 priming on TLR4 rechallenge. These results demonstrate that in human endothelial cells, prior activation of TLRs can have a significant impact on subsequent exposures and may contribute to the severity of the host response.
doi_str_mv 10.1016/j.trsl.2016.08.001
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5253081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S193152441630158X</els_id><sourcerecordid>1835632030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c580t-d589d27a62ed1cdc2056fad190d79d33c97758e1dc10f6774a273b4f867374f03</originalsourceid><addsrcrecordid>eNp9UtFqFTEQXUSxtfoDPsg--rLrJNlssiAFKWoLBYUq-BbSZLY3t7nJNckW-vdmubWoDz5lwpw5M3PONM1rAj0BMr7b9iVl39Ma9yB7APKkOSZSyI5IAk9rPDHScToMR82LnLcAwzjB8Lw5ooKPYmBw3Fx9jQVDcbq4GFodbFuix6SDwTbO68d33t1im9DgvsTU7pPbuXDTutBulp0OLQYbywa907416H1-2Tybtc_46uE9ab5_-vjt7Ly7_PL54uzDZWe4hNJZLidLhR4pWmKsocDHWVsygRWTZcxMQnCJxBoC8yjEoKlg18MsR8HEMAM7aU4PvPvleofW1D2S9modUKd7FbVTf2eC26ibeKc45QwkqQRvHwhS_LlgLmrn8rqCDhiXrIhkfGQU2NqLHqAmxZwTzo9tCKjVDbVVqxtqdUOBVNWNWvTmzwEfS37LXwHvDwCsMt05TCobh1V766reRdno_s9_-k-58S44o_0t3mPexiWFaoAiKlMF6mq9h_UcyMiAcPmD_QLiibJB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835632030</pqid></control><display><type>article</type><title>Potentiation and tolerance of toll-like receptor priming in human endothelial cells</title><source>Elsevier</source><creator>Koch, Stephen R ; Lamb, Fred S ; Hellman, Judith ; Sherwood, Edward R ; Stark, Ryan J</creator><creatorcontrib>Koch, Stephen R ; Lamb, Fred S ; Hellman, Judith ; Sherwood, Edward R ; Stark, Ryan J</creatorcontrib><description>Repeated challenge of lipopolysaccharide (LPS) alters the response to subsequent LPS exposures via modulation of toll-like receptor 4 (TLR4). Whether activation of other TLRs can modulate TLR4 responses, and vice versa, remains unclear. Specifically with regards to endothelial cells, a key component of innate immunity, the impact of TLR cross-modulation is unknown. We postulated that TLR2 priming (via Pam3Csk4) would inhibit TLR4-mediated responses while TLR3 priming (via Poly I:C) would enhance subsequent TLR4-inflammatory signaling. We studied human umbilical vein endothelial cells (HUVECs) and neonatal human dermal microvascular endothelial cells (HMVECs). Cells were primed with a combination of Poly I:C (10 μg/ml), Pam3Csk4 (10 μg/ml), or LPS (100 ng/ml), then washed and allowed to rest. They were then rechallenged with either Poly I:C, Pam3Csk4 or LPS. Endothelial cells showed significant tolerance to repeated LPS challenge. Priming with Pam3Csk4 also reduced the response to secondary LPS challenge in both cell types, despite a reduced proinflammatory response to Pam3Csk4 in HMVECs compared to HUVECs. Poly I:C priming enhanced inflammatory and interferon producing signals upon Poly I:C or LPS rechallenge, respectively. Poly I:C priming induced interferon regulatory factor 7, leading to enhancement of interferon production. Finally, both Poly I:C and LPS priming induced significant changes in receptor-interacting serine/threonine-protein kinase 1 activity. Pharmacological inhibition of receptor-interacting serine/threonine-protein kinase 1 or interferon regulatory factor 7 reduced the potentiated phenotype of TLR3 priming on TLR4 rechallenge. These results demonstrate that in human endothelial cells, prior activation of TLRs can have a significant impact on subsequent exposures and may contribute to the severity of the host response.</description><identifier>ISSN: 1931-5244</identifier><identifier>EISSN: 1878-1810</identifier><identifier>DOI: 10.1016/j.trsl.2016.08.001</identifier><identifier>PMID: 27567430</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Endothelial Cells - drug effects ; Endothelial Cells - metabolism ; Extracellular Signal-Regulated MAP Kinases - metabolism ; Human Umbilical Vein Endothelial Cells - drug effects ; Human Umbilical Vein Endothelial Cells - metabolism ; Humans ; Immune Tolerance - drug effects ; Interferon Regulatory Factor-7 - metabolism ; Interferons - metabolism ; Interleukin-6 - biosynthesis ; Internal Medicine ; Lipopeptides - pharmacology ; Lipopolysaccharides - pharmacology ; Nuclear Pore Complex Proteins - metabolism ; Phosphorylation - drug effects ; Poly I-C - pharmacology ; RNA-Binding Proteins - metabolism ; Toll-Like Receptors - metabolism ; Up-Regulation - drug effects</subject><ispartof>Translational research : the journal of laboratory and clinical medicine, 2017-02, Vol.180, p.53-67.e4</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c580t-d589d27a62ed1cdc2056fad190d79d33c97758e1dc10f6774a273b4f867374f03</citedby><cites>FETCH-LOGICAL-c580t-d589d27a62ed1cdc2056fad190d79d33c97758e1dc10f6774a273b4f867374f03</cites><orcidid>0000-0001-6142-5502</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27567430$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koch, Stephen R</creatorcontrib><creatorcontrib>Lamb, Fred S</creatorcontrib><creatorcontrib>Hellman, Judith</creatorcontrib><creatorcontrib>Sherwood, Edward R</creatorcontrib><creatorcontrib>Stark, Ryan J</creatorcontrib><title>Potentiation and tolerance of toll-like receptor priming in human endothelial cells</title><title>Translational research : the journal of laboratory and clinical medicine</title><addtitle>Transl Res</addtitle><description>Repeated challenge of lipopolysaccharide (LPS) alters the response to subsequent LPS exposures via modulation of toll-like receptor 4 (TLR4). Whether activation of other TLRs can modulate TLR4 responses, and vice versa, remains unclear. Specifically with regards to endothelial cells, a key component of innate immunity, the impact of TLR cross-modulation is unknown. We postulated that TLR2 priming (via Pam3Csk4) would inhibit TLR4-mediated responses while TLR3 priming (via Poly I:C) would enhance subsequent TLR4-inflammatory signaling. We studied human umbilical vein endothelial cells (HUVECs) and neonatal human dermal microvascular endothelial cells (HMVECs). Cells were primed with a combination of Poly I:C (10 μg/ml), Pam3Csk4 (10 μg/ml), or LPS (100 ng/ml), then washed and allowed to rest. They were then rechallenged with either Poly I:C, Pam3Csk4 or LPS. Endothelial cells showed significant tolerance to repeated LPS challenge. Priming with Pam3Csk4 also reduced the response to secondary LPS challenge in both cell types, despite a reduced proinflammatory response to Pam3Csk4 in HMVECs compared to HUVECs. Poly I:C priming enhanced inflammatory and interferon producing signals upon Poly I:C or LPS rechallenge, respectively. Poly I:C priming induced interferon regulatory factor 7, leading to enhancement of interferon production. Finally, both Poly I:C and LPS priming induced significant changes in receptor-interacting serine/threonine-protein kinase 1 activity. Pharmacological inhibition of receptor-interacting serine/threonine-protein kinase 1 or interferon regulatory factor 7 reduced the potentiated phenotype of TLR3 priming on TLR4 rechallenge. These results demonstrate that in human endothelial cells, prior activation of TLRs can have a significant impact on subsequent exposures and may contribute to the severity of the host response.</description><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - metabolism</subject><subject>Extracellular Signal-Regulated MAP Kinases - metabolism</subject><subject>Human Umbilical Vein Endothelial Cells - drug effects</subject><subject>Human Umbilical Vein Endothelial Cells - metabolism</subject><subject>Humans</subject><subject>Immune Tolerance - drug effects</subject><subject>Interferon Regulatory Factor-7 - metabolism</subject><subject>Interferons - metabolism</subject><subject>Interleukin-6 - biosynthesis</subject><subject>Internal Medicine</subject><subject>Lipopeptides - pharmacology</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Nuclear Pore Complex Proteins - metabolism</subject><subject>Phosphorylation - drug effects</subject><subject>Poly I-C - pharmacology</subject><subject>RNA-Binding Proteins - metabolism</subject><subject>Toll-Like Receptors - metabolism</subject><subject>Up-Regulation - drug effects</subject><issn>1931-5244</issn><issn>1878-1810</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9UtFqFTEQXUSxtfoDPsg--rLrJNlssiAFKWoLBYUq-BbSZLY3t7nJNckW-vdmubWoDz5lwpw5M3PONM1rAj0BMr7b9iVl39Ma9yB7APKkOSZSyI5IAk9rPDHScToMR82LnLcAwzjB8Lw5ooKPYmBw3Fx9jQVDcbq4GFodbFuix6SDwTbO68d33t1im9DgvsTU7pPbuXDTutBulp0OLQYbywa907416H1-2Tybtc_46uE9ab5_-vjt7Ly7_PL54uzDZWe4hNJZLidLhR4pWmKsocDHWVsygRWTZcxMQnCJxBoC8yjEoKlg18MsR8HEMAM7aU4PvPvleofW1D2S9modUKd7FbVTf2eC26ibeKc45QwkqQRvHwhS_LlgLmrn8rqCDhiXrIhkfGQU2NqLHqAmxZwTzo9tCKjVDbVVqxtqdUOBVNWNWvTmzwEfS37LXwHvDwCsMt05TCobh1V766reRdno_s9_-k-58S44o_0t3mPexiWFaoAiKlMF6mq9h_UcyMiAcPmD_QLiibJB</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Koch, Stephen R</creator><creator>Lamb, Fred S</creator><creator>Hellman, Judith</creator><creator>Sherwood, Edward R</creator><creator>Stark, Ryan J</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6142-5502</orcidid></search><sort><creationdate>20170201</creationdate><title>Potentiation and tolerance of toll-like receptor priming in human endothelial cells</title><author>Koch, Stephen R ; Lamb, Fred S ; Hellman, Judith ; Sherwood, Edward R ; Stark, Ryan J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c580t-d589d27a62ed1cdc2056fad190d79d33c97758e1dc10f6774a273b4f867374f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - metabolism</topic><topic>Extracellular Signal-Regulated MAP Kinases - metabolism</topic><topic>Human Umbilical Vein Endothelial Cells - drug effects</topic><topic>Human Umbilical Vein Endothelial Cells - metabolism</topic><topic>Humans</topic><topic>Immune Tolerance - drug effects</topic><topic>Interferon Regulatory Factor-7 - metabolism</topic><topic>Interferons - metabolism</topic><topic>Interleukin-6 - biosynthesis</topic><topic>Internal Medicine</topic><topic>Lipopeptides - pharmacology</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Nuclear Pore Complex Proteins - metabolism</topic><topic>Phosphorylation - drug effects</topic><topic>Poly I-C - pharmacology</topic><topic>RNA-Binding Proteins - metabolism</topic><topic>Toll-Like Receptors - metabolism</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koch, Stephen R</creatorcontrib><creatorcontrib>Lamb, Fred S</creatorcontrib><creatorcontrib>Hellman, Judith</creatorcontrib><creatorcontrib>Sherwood, Edward R</creatorcontrib><creatorcontrib>Stark, Ryan J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational research : the journal of laboratory and clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koch, Stephen R</au><au>Lamb, Fred S</au><au>Hellman, Judith</au><au>Sherwood, Edward R</au><au>Stark, Ryan J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potentiation and tolerance of toll-like receptor priming in human endothelial cells</atitle><jtitle>Translational research : the journal of laboratory and clinical medicine</jtitle><addtitle>Transl Res</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>180</volume><spage>53</spage><epage>67.e4</epage><pages>53-67.e4</pages><issn>1931-5244</issn><eissn>1878-1810</eissn><abstract>Repeated challenge of lipopolysaccharide (LPS) alters the response to subsequent LPS exposures via modulation of toll-like receptor 4 (TLR4). Whether activation of other TLRs can modulate TLR4 responses, and vice versa, remains unclear. Specifically with regards to endothelial cells, a key component of innate immunity, the impact of TLR cross-modulation is unknown. We postulated that TLR2 priming (via Pam3Csk4) would inhibit TLR4-mediated responses while TLR3 priming (via Poly I:C) would enhance subsequent TLR4-inflammatory signaling. We studied human umbilical vein endothelial cells (HUVECs) and neonatal human dermal microvascular endothelial cells (HMVECs). Cells were primed with a combination of Poly I:C (10 μg/ml), Pam3Csk4 (10 μg/ml), or LPS (100 ng/ml), then washed and allowed to rest. They were then rechallenged with either Poly I:C, Pam3Csk4 or LPS. Endothelial cells showed significant tolerance to repeated LPS challenge. Priming with Pam3Csk4 also reduced the response to secondary LPS challenge in both cell types, despite a reduced proinflammatory response to Pam3Csk4 in HMVECs compared to HUVECs. Poly I:C priming enhanced inflammatory and interferon producing signals upon Poly I:C or LPS rechallenge, respectively. Poly I:C priming induced interferon regulatory factor 7, leading to enhancement of interferon production. Finally, both Poly I:C and LPS priming induced significant changes in receptor-interacting serine/threonine-protein kinase 1 activity. Pharmacological inhibition of receptor-interacting serine/threonine-protein kinase 1 or interferon regulatory factor 7 reduced the potentiated phenotype of TLR3 priming on TLR4 rechallenge. These results demonstrate that in human endothelial cells, prior activation of TLRs can have a significant impact on subsequent exposures and may contribute to the severity of the host response.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27567430</pmid><doi>10.1016/j.trsl.2016.08.001</doi><orcidid>https://orcid.org/0000-0001-6142-5502</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1931-5244
ispartof Translational research : the journal of laboratory and clinical medicine, 2017-02, Vol.180, p.53-67.e4
issn 1931-5244
1878-1810
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5253081
source Elsevier
subjects Endothelial Cells - drug effects
Endothelial Cells - metabolism
Extracellular Signal-Regulated MAP Kinases - metabolism
Human Umbilical Vein Endothelial Cells - drug effects
Human Umbilical Vein Endothelial Cells - metabolism
Humans
Immune Tolerance - drug effects
Interferon Regulatory Factor-7 - metabolism
Interferons - metabolism
Interleukin-6 - biosynthesis
Internal Medicine
Lipopeptides - pharmacology
Lipopolysaccharides - pharmacology
Nuclear Pore Complex Proteins - metabolism
Phosphorylation - drug effects
Poly I-C - pharmacology
RNA-Binding Proteins - metabolism
Toll-Like Receptors - metabolism
Up-Regulation - drug effects
title Potentiation and tolerance of toll-like receptor priming in human endothelial cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T20%3A41%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potentiation%20and%20tolerance%20of%20toll-like%20receptor%20priming%20in%20human%20endothelial%20cells&rft.jtitle=Translational%20research%20:%20the%20journal%20of%20laboratory%20and%20clinical%20medicine&rft.au=Koch,%20Stephen%20R&rft.date=2017-02-01&rft.volume=180&rft.spage=53&rft.epage=67.e4&rft.pages=53-67.e4&rft.issn=1931-5244&rft.eissn=1878-1810&rft_id=info:doi/10.1016/j.trsl.2016.08.001&rft_dat=%3Cproquest_pubme%3E1835632030%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c580t-d589d27a62ed1cdc2056fad190d79d33c97758e1dc10f6774a273b4f867374f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1835632030&rft_id=info:pmid/27567430&rfr_iscdi=true